Turn Therapeutics (NASDAQ:TTRX) Trading Up 9.5% – Should You Buy?

Turn Therapeutics Inc. (NASDAQ:TTRX)’s stock price was up 9.5% on Wednesday . The stock traded as high as $5.97 and last traded at $5.53. Approximately 61,128 shares changed hands during trading, a decline of 6% from the average daily volume of 64,995 shares. The stock had previously closed at $5.05.

Analyst Ratings Changes

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $8.00 price target on shares of Turn Therapeutics in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

Turn Therapeutics Trading Up 3.2%

The company has a 50 day moving average of $4.31 and a 200 day moving average of $3.93. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.23 and a quick ratio of 2.23.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.03) EPS for the quarter.

Hedge Funds Weigh In On Turn Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Hodges Capital Management Inc. acquired a new position in Turn Therapeutics in the fourth quarter worth $39,000. LPL Financial LLC acquired a new position in Turn Therapeutics in the fourth quarter worth $51,000. Tamar Securities LLC acquired a new position in Turn Therapeutics in the fourth quarter worth $59,000. Composition Wealth LLC acquired a new position in Turn Therapeutics in the fourth quarter worth $63,000. Finally, Geode Capital Management LLC acquired a new position in Turn Therapeutics in the fourth quarter worth $68,000.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.